Related Experiment Videos
[Guacetisal: a new molecule with balsamic-antiphlogistic action. Clinical study]
Minerva Medica
|February 28, 1981
Summary
Guacetisal demonstrates good therapeutic activity and tolerability for airway inflammation, particularly chronic conditions. This balsamic-antiinflammatory molecule is easy to use, even in non-specialist settings.
Area of Science:
- Pharmacology
- Respiratory Medicine
Background:
- Airway inflammatory diseases represent a significant health burden.
- Effective and well-tolerated treatments are needed for chronic respiratory conditions.
Purpose of the Study:
- To evaluate the therapeutic efficacy and tolerability of guacetisal in patients with airway diseases.
Main Methods:
- An open clinical trial was conducted involving 45 patients (average age 64 years).
- Patients received guacetisal (500 mg Broncaspin capsules) for at least 7 days.
- Concomitant use of certain medications was avoided, while others were used as needed.
Main Results:
- Guacetisal showed good therapeutic activity in treating airway inflammation, especially chronic forms.
- The molecule was well-tolerated by patients.
- Ease of use was noted, suggesting suitability for non-specialist environments.
Conclusions:
- Guacetisal is a promising balsamic-antiinflammatory agent for airway inflammatory conditions.
- Its favorable tolerability profile supports its clinical utility and ease of administration.